Fda Drug Approval Process Flawed: The Truth Exposed
By www.menhealthonline.biz
Years and years the FDA has told the American public that they are here to serve in our best interest. They have told us that the reason we cannot import medication from Canada is because it is not safe. They have told us the reason that America doesn’t have price controls is because they want to promote the creation of truly new innovative drugs. What they failed to mention is how none of these claims are true, and rather than serving as a guard against potential hazards and dangers, they are really here to utilize there position in order to manipulate the system for their own personal gain.
The best example that displays several different types of corruption that are taking place in the FDA is the case of Vioxx and the COX-2 inhibitors. COX-2 inhibitors are a class of drug that help to relieve the symptoms of arthritis. Vioxx had been heavily promoted to both doctors and the public and was used by over 2 million people giving it a yearly sale of over $2.5 billion dollars. Suddenly, on September 30, 2004, Vioxx was withdrawn from the market after a clinical trial showed that it more than doubled the risk of heart attacks and strokes.
The FDA failed to mention that they had pushed Vioxx through the approval stage so fast, they failed to do the necessary studies to prevent harm to the American public. They made one mistake, and they corrected it by getting Vioxx off the market, right? Well they followed it up by going against the better judgment of most professionals in their field by leaving all the other COX-2 inhibitors like Celebrex and Bextra on the market.
Strike two. It didn’t take long and within several months there were reports that the other drugs were experiencing the same problems and they were taken off the market as well.
In lieu of all this controversy, the FDA created an advisory panel to look into the case. The panel consisted of two advisory committees; one for arthritis and the other for drug safety. After several days of deliberation, the two panels concluded by a narrow margin that even though there was no doubt that the COX-2 inhibitors increased both heart attacks and strokes, the benefits outweighed the risks and all the inhibitors would be allowed to return to the market just with stronger